CDR-Life products

CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based immunotherapies against intracellular tumor antigens for treatment of a variety of solid tumor malignancies. In addition, the company has a superior trispecific BCMA therapy positioned for partnering as well as a therapeutic antibody fragment for treatment of a blinding retinal disease, which is partnered with Boehringer Ingelheim.